Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate in the 25^th Annual Needham Virtual Healthcare Conference.

25th Annual Needham Virtual Healthcare Conference

Fireside Chat: Monday, April 13, 2026, at 3:00 p.m. EDT

The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations', under ‘Events', via the ‘Investors' section of Immunocore's website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company's most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Head of Communications

T: +44 (0) 7458030732

E: sebastien.desprez@immunocore.com

Follow on LinkedIn: @Immunocore

Investor Relations

Morgan Morse

T: +1 (215) 384-4781

E: ir@immunocore.com